National Prostate Cancer Audit: State of the Nation Report 2024
This report shows that Black men have higher rates of stage 3 and stage 4 prostate cancer diagnosis compared to white men, and Black men in their 60s who get a later diagnosis are also less likely to get NICE-approved treatment on the NHS.
PSA diagnostic case studies

Dr Sam Merriel and Dr Olly Hulson cover some case studies common to Primary Care, to explore early diagnosis and diagnostic pathways through real-world scenarios.
Exploring radiotherapy treatment, pathways and supportive care – a collaboration with RadChat

Prostate Cancer UK teams up with RadChat, the award-winning, first Therapeutic Radiographer-led podcast, to deliver this valuable webinar about radiotherapy in prostate cancer treatment.
Prostate Cancer Essentials: Part 2 – Diagnosing and Staging

A course providing healthcare professionals with an increased understanding of how prostate cancer is diagnosed.
Using real world data to bridge the evidence gap left by prostate cancer screening trials
How Real-World Data can demonstrate reduction in harms of prostate cancer screening and inform the future of diagnostics to improve early diagnosis.
The modern prostate cancer diagnostic pathway

Dr. Olly Hulson provides an overview of the modern prostate cancer diagnostic pathway.
PSA consensus recommendations and implications for practice

Dr. Sam Merriel presents PSA consensus recommendations and implications for practice.
Lived experience conversation

Meg Burgess, Specialist Nurse at Prostate Cancer UK, leads a lived experience conversation with Tony, Junior, and Patrick.
Remote consultations: experiences of UK patients with prostate cancer during the COVID-19 pandemic
The article highlights that UK prostate cancer patients preferred in-person consultations for key discussions but accepted remote consultations for routine follow-ups, suggesting a balanced approach with critical decisions made face-to-face.
Prostate mpMRI in the UK: the state of the nation
The article discusses how advancements in multiparametric MRI (mpMRI) are enhancing prostate cancer diagnosis by reducing unnecessary biopsies and targeting significant cancers, despite ongoing challenges like geographical variation and limited resources.